- Home
- Deep Dive
- Blogs
- MOREPENLAB
- Q3 FY26
Morepen Laboratories Reports Strong Q3 FY26 Performance Driven by Medical Devices
Frequently Asked Questions
Morepen Laboratories Limited reported a consolidated gross revenue of 488 crore for Q3 FY26, marking a 17% increase from Q2 FY26.
The Pharma Business contributed 285 crore to the standalone gross revenue in Q3 FY26, representing 62% of the total business segments.
The Medical Devices segment generated a total revenue of 177 crore in Q3 FY26, showing a significant 44% growth compared to Q3 FY25. This segment accounted for 38% of the total business segments.
Top-selling products in the Medical Devices segment include Blood Glucose meters, BP Monitors, Nebulisers, Thermometers, Ortho Supports, and Pregnancy Kits.
For Q3 FY26, the consolidated EBITDA was 50 crore, a 42% increase from Q2 FY26. The consolidated PAT stood at 28 crore, an 83% increase from Q2 FY26.
In Q3 FY26, India contributed 64.1% of the gross revenue, followed by Europe at 17.1%, Asia at 13.2%, S. America at 2.7%, and USA at 3%.
Cumulatively year-to-date, Morepen has sold 16.85 million Gluco Meters and 2.33 billion Gluco Strips, indicating a strong customer base in this category.
Related Blogs
A NOTE FROM THE FOUNDER
Hey, I'm Aaditya, founder of Multibagg AI. If you enjoyed reading this article, you've only seen a small part of what's possible with Multibagg AI. Here's what you can do next:
Ask Iris
Get answers from annual reports, concalls, and investor presentations
Discovery
Find hidden gems early using AI-tagged companies
Portfolio
Connect your portfolio and understand what you really own
Timeline
Follow important company updates, filings, deals, and news in one place
It's all about thinking better as an investor. Welcome to a smarter way of doing stock market research.
